AI Investment Edge: Stocks, Markets & Money copertina

AI Investment Edge: Stocks, Markets & Money

AI Investment Edge: Stocks, Markets & Money

Di: iPulse AI by Future Edge Group
Ascolta gratuitamente

Offerte di stagione | 0,99 €/mese per i primi 3 mesi

A seguire 9,99 €/mese – si applicano condizioni. Puoi disdire mensilmente.
A proposito di questo titolo
 Clear, evidence-led conversations about AI investment research, stock theses, and the assumptions behind market forecasts. From iPulse AI, the Open Agentic Investment Research Platform by Future Edge Group: explore the sources and dated research at https://ipulseai.com. Research, not investment advice.

ipulseai.substack.comRusslansing Ramdowar Economia Finanza personale Politica e governo
Episodi
  • EP 41 | Nu Holdings Stock Analysis: Will Nubank Leave Big Banks Behind?

    EP 41 | Nu Holdings Stock Analysis: Will Nubank Leave Big Banks Behind?
    Nov 8 2026
    EP 41 | Nu Holdings Stock Analysis: Will Nubank Leave Big Banks Behind?AI Investment Edge: Stocks, Markets & Money. Research as of 8 November 2026. Nubank has passed a billion dollars in quarterly profit. Will cheap digital distribution leave established banks behind, or does credit risk narrow the advantage?Nu Holdings Class A ordinary share, NU.NYSE / USD. Dated provider close US$12.03 on 6 November, checked 8 November; not a live Sunday quote. Current price-adjusted weighted ratings: Strong Buy at both horizons; separate Strong Buy & Keep action. Original weighted endpoints: 18 September 2027 and 18 September 2031, not new rolling horizons. Unrounded endpoint calculations imply +38.61% and +169.59% cumulative price returns. Public delivery-rounded target math displays +38.65%/+169.33%; the methods' last digits differ. No future cash dividend assumed; cash-inclusive illustration has no dividend uplift, before tax/fees and without reinvestment.The financial tests. Latest actual Q2, released 13 August: IFRS revenue US$5.51bn and net income US$1.06bn. Managerial revenue US$5.88bn has a different scope. Risk-adjusted interest margin rose to 12.40%, expressly not a floor; early arrears improved, late arrears rose. Brazil core capital fell from 13.00% to 11.90%; US$45.33bn deposits are customer liabilities. H1 physical/intangible investment US$100.47m is separate from US$336.09m infrastructure/data operating expense, not all identified AI spending. H1 bank cash moved US$15.00bn to US$13.55bn with loan, deposit, investing, financing and FX flows; this is not industrial free cash flow.The hinge. Low servicing cost and cross-selling must survive seasoned defaults, funding costs, local capital limits and FX. Fourteen correlated AI contributions disagree about bank multiples versus an international technology premium. Mexico began bank operations in August; September US launch was via Lead Bank, not Nu's own unrestricted US charter. Q3 results are upcoming 12 November; Investor Day 8 December. Later model milestones are assumptions. Both upside expansion and downside credit/currency shocks matter.Research: AI Consensus and complete quarter path · AI Opinions · Fundamentals · Covered-asset rankings · Methodology.Related episodes: PayPal Episode 11, customer versus corporate cash (listen/read, YouTube); Adyen Episode 31, payments scale versus bank credit risk (listen/read, YouTube); BNP Paribas Episode 33, profit versus distributable bank capital (listen/read, YouTube). Separate last stock: RxSight Episode 40 (listen/read, YouTube). Historical forecasts are not current Nu forecasts.Primary sources: Q2 results; interim statements; official results and call; event calendar. Upstream manual display QA remains open; primary verification is separate.For the bigger picture, visit iPulse AI to explore our complete rankings of covered assets, discover the Strongest Buys, and see the research behind the ratings, all in one place. Primary research conducted through the iPulse AI platform by Future Edge Group. Like, comment and subscribe. We are publishing a new podcast every day of the week except Thursday. Stay tuned for the next podcast on Edenred. This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit ipulseai.substack.com
    Mostra di più Mostra meno
    16 min
  • EP 40 | RxSight Stock Analysis: Will a Cataract Breakthrough Make Investors Rich?

    EP 40 | RxSight Stock Analysis: Will a Cataract Breakthrough Make Investors Rich?
    Nov 7 2026
    RxSight: Will a Cataract Breakthrough Make Investors Rich?AI Investment Edge · Research as of 7 November 2026. RxSight sells adjustable lenses implanted during cataract surgery and the light-delivery equipment used afterward. Can better clinical support restore repeat demand?Explore AI Consensus, AI Opinions, Profile & Fundamentals and rankings of covered assets and Strongest Buys.Four financial tests. Q3 revenue US$24.59m fell 19%; net loss widened to US$16.22m. Lens volume fell about 11% despite installed-base growth. Product gross margin improved to 73.6% from Q2’s 71.2%, but remained below 79.9% a year earlier. September cash and short-term investments were US$254.68m, including US$60m received from Alcon. Nine-month physical capex was US$3.89m; R&D expense US$27.92m is separate operating investment.The cash bridge. Nine-month operating cash +US$24.79m includes the US$60m Alcon receipt. Removing only that receipt gives US$35.21m outflow; subtracting capex gives US$39.10m outflow. This is derived arithmetic, not company normalized free cash flow or a forecast run rate. Other collaboration costs and working-capital effects remain.Fixed-date scenarios. Dated 6 November provider close US$4.54, not live Saturday. Exact weighted targets rounded to US$7.06 on 18 September 2027 and US$16.79 on 18 September 2031 imply +55.57% and +269.74% cumulative price gains using unrounded endpoints. Public delivery-rounded percentages differ slightly. No dividend is paid or assumed, so no dividend uplift. Current public weighted ratings: Strong Buy at both horizons; separate Strong Buy & Keep action. All twenty forecast steps rise, but the stock need not follow a smooth path. Bull/bear mechanisms depend on adoption, workflow, spending and development; separate unweighted stress paths are not blended into the weighted base.Alcon and the real test. US$50m of the upfront receipt became nonrefundable on 28 October. That is not another cash receipt or automatically US$50m immediate Q4 revenue. License recognition at a point in time and development recognized as it progresses are distinct; no exact Q4 recognition split is specified. Up to US$140m further milestones remain conditional; 30% royalties concern successful collaboration-product net sales under contract terms. No cash floor, automatic acquisition or immunity from dilution. Monitor recurring lens demand, product margin, operating cash consumption and development progress.The July research predates the July 6 public deal disclosure, July CEO transition and August guidance withdrawal. Those developments were already public before September; October/November commercial changes and weak latest demand are later evidence. The prior public stock was PepsiCo Episode 39, a distinct consumer-business comparison.Related conversations: Boston Scientific, Episode 25 — listen / watch; Medtronic, Episode 27 — listen / watch; GSK, Episode 36 — listen / watch. Different businesses, linked by adoption, investment and cash generation.Primary sources: Q3 results; Q3 Form 10-Q; Q2 results; July 6 update; official November presentation; research methodology. AI perspectives are correlated, not independent human analysts.Primary research conducted through the iPulse AI platform by Future Edge Group. Like, comment and subscribe. Next: Nu Holdings, known as Nubank. This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit ipulseai.substack.com
    Mostra di più Mostra meno
    15 min
  • EP 39 | PepsiCo Stock Analysis: Will the Cash Recovery Last?

    EP 39 | PepsiCo Stock Analysis: Will the Cash Recovery Last?
    Nov 5 2026
    PepsiCo sold more snacks and generated more operating cash, but its free cash flow still fell slightly short of cash dividends for the first 36 weeks. Can the business keep winning shoppers while protecting margins and funding the payout?Research checked 5 November 2026. PEP.NASDAQ ordinary USD shares, ISIN US7134481081. Recording reference $142.42, the 4 November New York daily close used by the platform. The independent Alpaca IEX daily bar closed at $142.45 on that date, a separate exchange-only print.Public weighted Partial Sell for September 2027 and Buy for September 2031, with separate Watch for Better Entry. Ratings use the platform’s net-yield and reinvestment method.Fixed September 18, 2027 and 2031 targets $141.46 and $191.41. Cumulative price -0.67% and +34.40%. Flat quarterly $1.48, $5.92 annualized, assumes $4.44 and $28.12 future gross cash. September 2026 already paid. Gross cash-plus-price +2.45% and +54.15%, before tax and fees, without reinvestment.PepsiCo AI Consensus · PepsiCo AI Opinions · PepsiCo Profile & Fundamentals · Complete rankings of covered assets and Strongest BuysEarnings and margins. Q3 sales +5.6% reported and +3.1% organic. GAAP EPS +17% and core +2%. Reported margin up, core down. North American savory snack volume improved while net pricing pressured sales.Debt and investment. $51.88bn debt and $11.16bn cash plus short investments. $7.95bn operating cash less $2.18bn capex plus $89m of property sales gives $5.86bn of company free cash flow over 36 weeks. Cash dividends paid were $5.94bn.Cash and restricted cash bridge. $9.20bn plus $7.95bn operations, less $2.35bn investing, $3.90bn financing and $175m FX, ends at $10.73bn within rounding.Cases test repeat purchases and productivity versus discount dependency and tighter margins. Upside tail is unexpected input cost relief. Downside tail is a demand shock from broad food-policy changes. Advisors disagree on cash conversion, demand durability and valuation.All 20 September model steps rise from their original anchor. The initial quarter remains below the November price. July Q2 evidence was available in September, while the October Q3 update came later. Boeing is the separate last-stock comparison. Watch repeat purchases, core margin and normalized cash coverage of dividends.EP 32 | AXA Stock Analysis: Is This Dividend Giant Ready to Soar?. Listen on Substack · Watch on YouTube.EP 35 | Proximus Stock Analysis: Can a Cash Turnaround Send It Soaring?. Listen on Substack · Watch on YouTube.EP 36 | GSK Stock Analysis: Can New Drugs Beat the Patent Cliff?. Listen on Substack · Watch on YouTube.8 October Q3 2026 results · PepsiCo Q3 2026 Form 10-Q · 9 July Q2 prepared management remarks · July board dividend declaration · iPulse AI methodologyFor the bigger picture, visit iPulse AI to explore our complete rankings of covered assets, discover the Strongest Buys, and see the research behind the ratings, all in one place.Primary research conducted through the iPulse AI platform by Future Edge Group.Like, comment and subscribe.We are publishing a new podcast every day of the week except Thursday. Stay tuned for the next podcast on RxSight. This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit ipulseai.substack.com
    Mostra di più Mostra meno
    19 min
adbl_web_anon_alc_button_suppression_t1
Ancora nessuna recensione